These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8667619)

  • 1. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma.
    Goydos JS; Elder E; Whiteside TL; Finn OJ; Lotze MT
    J Surg Res; 1996 Jun; 63(1):298-304. PubMed ID: 8667619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA.
    Jerome KR; Domenech N; Finn OJ
    J Immunol; 1993 Aug; 151(3):1654-62. PubMed ID: 8393050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients.
    Kotera Y; Fontenot JD; Pecher G; Metzgar RS; Finn OJ
    Cancer Res; 1994 Jun; 54(11):2856-60. PubMed ID: 7514493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
    Jerome KR; Barnd DL; Bendt KM; Boyer CM; Taylor-Papadimitriou J; McKenzie IF; Bast RC; Finn OJ
    Cancer Res; 1991 Jun; 51(11):2908-16. PubMed ID: 1709586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.
    Karanikas V; Thynne G; Mitchell P; Ong CS; Gunawardana D; Blum R; Pearson J; Lodding J; Pietersz G; Broadbent R; Tait B; McKenzie IF
    J Immunother; 2001; 24(2):172-83. PubMed ID: 11265775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
    Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
    Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-tumor activity and immune responses induced by human cancer-associated mucin core peptide].
    Ma Y; Yuan M; Fei L
    Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):419-21. PubMed ID: 9387291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human B cell immune response to selected epitopes of the polymorphic epithelial mucin (PEM) in cancer patients.
    Nuti M; Rughetti A; Turchi V; Apollonj-Ghetti C; Scambia G; Frati L
    In Vivo; 1993; 7(6B):645-7. PubMed ID: 7514896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
    Karanikas V; Hwang LA; Pearson J; Ong CS; Apostolopoulos V; Vaughan H; Xing PX; Jamieson G; Pietersz G; Tait B; Broadbent R; Thynne G; McKenzie IF
    J Clin Invest; 1997 Dec; 100(11):2783-92. PubMed ID: 9389743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
    Loveland BE; Zhao A; White S; Gan H; Hamilton K; Xing PX; Pietersz GA; Apostolopoulos V; Vaughan H; Karanikas V; Kyriakou P; McKenzie IF; Mitchell PL
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):869-77. PubMed ID: 16467101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
    von Mehren M; Arlen P; Tsang KY; Rogatko A; Meropol N; Cooper HS; Davey M; McLaughlin S; Schlom J; Weiner LM
    Clin Cancer Res; 2000 Jun; 6(6):2219-28. PubMed ID: 10873071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
    Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
    Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does pregnancy immunize against breast cancer?
    Agrawal B; Reddish MA; Krantz MJ; Longenecker BM
    Cancer Res; 1995 Jun; 55(11):2257-61. PubMed ID: 7538899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.